{"type":"trials","record":{"id":41374,"source_id":"clinicaltrials-gov","external_id":"NCT07205887","title":"A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO","brief_summary":"EYE-RES-104 is a randomized, dose-masked study of intravitreal EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). The study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of EYE103 via IVT or a high dose of EYE103 via IVT. 40 participants will be enrolled in each cohort. Enrollment timing for each cohort will be sequenced into specific arms of the study at the Sponsor's discretion. All participants in the study will receive a total of 3 injections of EYE103 into the study eye, spaced at 4 weeks apart. All participants will return at designated time points following each injection for safety and efficacy assessments. The Week 12 Visit will serve as the end of study visit for all participants.","overall_status":"Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"EyeBiotech Ltd.","enrollment":160,"countries":["United States"],"start_date":"2025-09-12","completion_date":"2028-06-30","last_update_date":"2026-09-04","source_url":"https://clinicaltrials.gov/study/NCT07205887","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"Super Tuscan","age_range":"18 Years","comparator":null,"organization":"EyeBiotech Ltd.","interventions":["EYE103","Aflibercept 2.0 mg"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change from baseline in Best-Corrected Visual Acuity measured using the standardized Early Treatment of Diabetic Retino…","Changes in retinal central subfield thickness (CST) based on spectral domain optical coherence tomography (SDOCT) — Dur…","Changes in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Neovascular Age-Related Macular Degeneration (NVAMD)","Branch Retinal Vein Occlusion (BRVO)","EYE103","Aflibercept 2.0 mg"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07205887","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-09-12 to 2028-06-30","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.801Z","intervention":["EYE103","Aflibercept 2.0 mg"],"participants":160,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change from baseline in Best-Corrected Visual Acuity measured using the standardized Early Treatment of Diabetic Retino…","Changes in retinal central subfield thickness (CST) based on spectral domain optical coherence tomography (SDOCT) — Dur…","Changes in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41374","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}